


SYNTHESIS OF CHIRAL TRIPEPTIDES BY ASYMMETRIC HYDROGENATION OF DEHYDROTRIPEPTIDES  
 REMARKABLE EFFECTS OF N-PROTECTING GROUPS ON STEREOSELECTIVITY AND REACTIVITY

Iwao Ojima\* and Noriko Yoda


Sagam Chemical Research Center, Nishi Ohnuma 4-4-1, Sagamihara, Kanagawa 229, Japan

*Summary* Dehydrotripeptides,  $X-\overset{*}{\text{CH}}(\text{R}^2)-\Delta\text{Phe}-\overset{*}{\text{CH}}(\text{R}^1)\text{COOMe}$  ( $\lambda$   $X = \text{tBOC-NH, CBZ-NH, CF}_3\text{CONH and N}_3$ ), were employed for the asymmetric hydrogenation catalyzed by chiral rhodium complexes and it was found that  $\text{tBOC-}\lambda$  brought about by far the best results. Stereoselective dideuteration of a  $\text{tBOC-}\lambda$  was successfully performed.

Recently, new synthetic route to the chiral dipeptides has been developed by using the asymmetric hydrogenation of dehydrodipeptides catalyzed by chiral rhodium complexes,<sup>1,2</sup> and it has been disclosed that the dehydrodipeptides of the type  $\lambda$  are very good substrates for the reaction to achieve quite high stereoselectivities<sup>1</sup> whereas the dehydrodipeptides of the type  $\kappa$  realize




only moderate to fairly good stereoselectivities.<sup>2</sup> Although these reported results provide interesting and significant informations about the applicability of homogeneous asymmetric hydrogenation to peptide synthesis, the chiral dipeptides so far obtained in the asymmetric hydrogenation of the type  $\lambda$  and  $\kappa$  dehydrodipeptides where  $\text{R}^1$  is methyl or phenyl, are not necessarily good building blocks for polypeptide syntheses since it is hard to remove the acetyl or benzoyl protecting group. Accordingly, we prepared dehydrotripeptides of the type  $\lambda$  where  $X$  is *t*-butoxycarbonyl ( $\text{tBOC}$ ), benzyloxycarbonyl ( $\text{CBZ}$ ), or trifluoroacetyl, which could provide versatile tri-



peptide building blocks after the asymmetric hydrogenation. Now, we describe here effective asymmetric hydrogenation of the type  $\lambda$  dehydrotripeptides and remarkable effects of N-protecting groups on stereoselectivity and reactivity.


The dehydrotripeptides ( $\lambda$ ) where  $\text{R}^1$  is phenyl and  $\text{R}$  is methyl in the present study, were easily prepared by the reaction of azlactones ( $\lambda$ ) with  $\alpha$ -amino acid ester hydrochlorides ( $\lambda$ ) in

the presence of N-methylmorpholine (NMM) in chloroform at room temperature in good yields (eq 1)<sup>3</sup>



For the comparison purpose, N<sub>3</sub>CH<sub>2</sub>CO-ΔPhe-(*S*)-Leu-OMe ( $\mathfrak{Zd}$ ) which is equivalent to Gly-ΔPhe-(*S*)-Leu-OMe, was also prepared in a similar manner<sup>3</sup>

The asymmetric hydrogenation of  $\mathfrak{Z}$  thus prepared revealed that both the catalyst efficiency and the stereoselectivity of the reaction was strongly governed by the sort of N-protecting group



For instance, the asymmetric hydrogenation of  $\mathfrak{Za-l}$ ,  $\mathfrak{Zb} \sim \mathfrak{Zd}$  where R<sup>z</sup> is hydrogen and R<sup>k</sup> is isobutyl (*S*) by using Ph-CAPP-Rh<sup>+</sup> as catalyst<sup>4</sup> (40°C in ethanol) gave the following results  
 $\mathfrak{Za-l}$  (cat 1.0 mol%, 10 atm of H<sub>2</sub>, 45 h) 100% conversion, (*R,S*)/(*S,S*) = 96.9/3.1,  $\mathfrak{Zb}$  (cat 2.0 mol%, 10 atm of H<sub>2</sub>, 40 h) 82% conversion, (*R,S*)/(*S,S*) = 85.4/14.6,  $\mathfrak{Zc}$  (cat 5.0 mol%, 50 atm of H<sub>2</sub>, 50 h) 93% conversion, (*R,S*)/(*S,S*) = 61.5/38.5,  $\mathfrak{Zd}$  (cat 5.0 mol%, 50 atm of H<sub>2</sub>, 45 h) 0% conversion<sup>5,10</sup> As typically exemplified in these results,  $\mathfrak{Z}$  bearing <sup>t</sup>BOC group ( $\mathfrak{Za}$ ) brings about by far the best stereoselectivity as well as catalyst efficiency As for the asymmetric hydrogenation of  $\mathfrak{Zb}$ , we further carried out the reaction with higher concentration of chiral catalysts and found that high stereoselectivities could be realized by using 5.0 mol% of the chiral catalyst, and in the case of diPAMP-Rh<sup>+</sup> catalyst, 2.0 mol% concentration was enough to attain high stereoselectivity Results are listed in Table 1<sup>10</sup>

The asymmetric hydrogenation of  $\mathfrak{Za}$  series,  $\mathfrak{Za-l} \sim \mathfrak{Za-3}$ , proceeded smoothly by using 1.0 mol% of chiral catalysts to give the corresponding tripeptides ( $\mathfrak{La-l} \sim \mathfrak{La-3}$ ) in quantitative yields Results are summarized in Table 2<sup>10</sup>

In connection with the regiospecific and stereoselective labeling of polypeptides, we carried out the dideuteration of  $\mathfrak{Za-l}$  as a model system by using Ph-CAPP-Rh<sup>+</sup> and diPAMP-Rh<sup>+</sup> as catalysts<sup>4,6</sup> The reactions were run with 1.0 mol% of the chiral catalyst<sup>10</sup> in ethanol at 40°C and 10 atm of hydrogen for 18 h, and the corresponding dideuteriotripeptides were obtained in quantitative yields without any scrambling of deuterium (eq 3), Ph-CAPP-Rh<sup>+</sup> (*R,R,S*)/(*S,S,S*) = 93.0/7.0, diPAMP-Rh<sup>+</sup> (*R,R,S*)/(*S,S,S*) = 2.6/97.4

In conclusion, it is demonstrated that the asymmetric hydrogenation catalyzed by chiral rhodium complexes is readily applicable to the asymmetric synthesis of tripeptide building blocks by the entry of <sup>t</sup>BOC for protecting N-terminus, and also to the stereoselective labeling of these building blocks An application of this method to the asymmetric synthesis of Enkephalin analog will be described in the following paper

Table 1 Asymmetric Hydrogenation of CBZ-Gly- $\Delta$ Phe-(*S*)-Leu-OMe (**3b**)<sup>a</sup>


| Entry | Chiral Ligand         | Cat (mol %) | Conditions     |       |      | Conversion (%) <sup>b</sup> | (R,S)/(S,S) <sup>b</sup><br>(+0.1%) |
|-------|-----------------------|-------------|----------------|-------|------|-----------------------------|-------------------------------------|
|       |                       |             | H <sub>2</sub> | Press | Temp | Time                        |                                     |
| 1     | (+)-BPPM <sup>e</sup> | 2.0         | 10 atm         | 40°C  | 65 h | 88                          | 20.8/79.2                           |
| 2     |                       | 5.0         | 10 atm         | 40°C  | 65 h | 100                         | 8.0/92.0                            |
| 3     | (-)-BPPM <sup>d</sup> | 2.0         | 10 atm         | 40°C  | 47 h | 79                          | 85.8/14.2                           |
| 4     |                       | 5.0         | 10 atm         | 40°C  | 42 h | 100                         | 93.0/7.0                            |
| 5     | Ph-CAPP <sup>e</sup>  | 2.0         | 10 atm         | 40°C  | 40 h | 82                          | 86.4/13.6                           |
| 6     |                       | 5.0         | 10 atm         | 40°C  | 40 h | 100                         | 94.1/5.9                            |
| 7     | (+)-DIOP <sup>f</sup> | 5.0         | 10 atm         | 40°C  | 40 h | 100                         | 27.6/72.4                           |
| 8     | (-)-DIOP <sup>f</sup> | 5.0         | 10 atm         | 40°C  | 40 h | 100                         | 75.9/24.1                           |
| 9     | dIPAMP <sup>g</sup>   | 2.0         | 10 atm         | 40°C  | 65 h | 100                         | 3.3/96.7                            |
| 10    |                       | 5.0         | 50 atm         | 40°C  | 42 h | 100                         | 3.6/96.4                            |

<sup>a</sup> All reactions were run with 0.3 mmol of **3b** and  $0.6 \sim 1.5 \times 10^{-2}$  mmol of chiral catalyst in ethanol (9 ml). <sup>b</sup> Determined by HPLC analysis (see note 5). <sup>c</sup> See ref. 7. <sup>d</sup> See ref. 8. <sup>e</sup> See ref. 4. <sup>f</sup> See ref. 9. <sup>g</sup> See ref. 6.

Table 2 Asymmetric Hydrogenation of <sup>t</sup>BOC-Dehydrotripeptides (**3a**)<sup>a</sup>

| Entry | Substrate                                                            | Chiral Ligand | Tripeptide               |                              |
|-------|----------------------------------------------------------------------|---------------|--------------------------|------------------------------|
|       |                                                                      |               | (R,S)/(S,S) <sup>b</sup> | (S,R,S)/(S,S,S) <sup>b</sup> |
| 1     | <sup>t</sup> BOC-Gly- $\Delta$ Phe-( <i>S</i> )-Leu-OMe              | Ph-CAPP       | 96.9/3.1                 |                              |
| 2     | <b>3a-1</b>                                                          | (-)-BPPM      | 94.0/6.0                 |                              |
| 3     |                                                                      | (+)-BPPM      | 8.0/92.0                 |                              |
| 4     |                                                                      | (-)-DIOP      | 84.4/15.6                |                              |
| 5     |                                                                      | (+)-DIOP      | 33.5/66.5                |                              |
| 6     |                                                                      | dIPAMP        | 1.1/98.9                 |                              |
| 7     | <sup>t</sup> BOC-( <i>S</i> )-Ala- $\Delta$ Phe-( <i>S</i> )-Leu-OMe | Ph-CAPP       | 92.5/7.5                 |                              |
| 8     | <b>3a-2</b>                                                          | (-)-BPPM      | 90.8/9.2                 |                              |
| 9     |                                                                      | (+)-BPPM      | 17.9/82.1                |                              |
| 10    |                                                                      | dIPAMP        | 5.0/95.0                 |                              |
| 11    | <sup>t</sup> BOC-( <i>S</i> )-Phe- $\Delta$ Phe-( <i>S</i> )-Leu-OMe | Ph-CAPP       | 94.4/5.6                 |                              |
| 12    | <b>3a-3</b>                                                          | (-)-BPPM      | 89.0/11.0                |                              |
| 13    |                                                                      | (+)-BPPM      | 24.9/75.1                |                              |
| 14    |                                                                      | dIPAMP        | 4.1/95.9                 |                              |

<sup>a</sup> All reactions were run with 0.30 mmol of **3a** and  $3.0 \times 10^{-3}$  mmol of catalyst in ethanol (9.0 ml) at 40°C and 10 atm of hydrogen for 18 h. <sup>b</sup> Determined by HPLC analysis (+0.1%)(see note 5).



**Acknowledgment** The authors are grateful to Dr W S Knowles of Monsanto Company for his generous gift of a chiral ligand, diPAMP

#### References and Notes

- (a) I Ojima, T Suzuki, *Tetrahedron Lett*, **21**, 1239 (1980) (b) I Ojima, T Kogure, N Yoda, T Suzuki, M Yatabe, T Tanaka, *J Org Chem*, **47**, 1329 (1982) (c) D Meyer, J -P Poulin, H B Kagan, H Levine-Pinto, J -L Morgat, *J Org Chem*, **45**, 4680 (1980) (d) K Onuma, T Ito, A Nakamura, *Chem Lett*, 481 (1980)
- A Kleemann, J Martens, M Samson, W Bergstein, *Synthesis*, 740 (1981)
- $\mathbf{3a-1}$  mp 192-193°C,  $[\alpha]_D^{20}$  -25 3° (c 1 002, MeOH)  $\mathbf{3a-2}$  mp 163-164°C,  $[\alpha]_D^{20}$  -50 0° (c 1 001, MeOH)  $\mathbf{3a-3}$  mp 162 5-163°C,  $[\alpha]_D^{20}$  -77 2° (c 1 002, MeOH)  $\mathbf{3b}$  mp 133 5-135 5°C,  $[\alpha]_D^{20}$  -16 3° (c 1 003, MeOH)  $\mathbf{3c}$  mp 188-189 5°C,  $[\alpha]_D^{20}$  -18 9° (c 1 005, MeOH)  $\mathbf{3d}$  mp 152-153 5°C,  $[\alpha]_D^{20}$  -5 7° (c 1 001, MeOH) All compounds gave satisfactory elemental analyses and spectral data
- Ph-CAPP stands for (2*S*,4*S*)-N-(N-phenylcarbonyl)-4-diphenylphosphino-2-diphenylphosphino-methylpyrrolidine I Ojima and N Yoda, *Tetrahedron Lett*, **21**, 1051 (1980)
- HPLC analyses were carried out by using a reversed phase column packed with TOYO SODA LS 410K (ODS SIL) and aqueous methanol as eluant
- diPAMP stands for (1*R*,2*R*)-1,2-ethanediylbis[(o-anisylphenyl)phosphine] B D Vineyard, W S Knowles, M J Sabacky, G L Bachmann, and D J Weinkauff, *J Am Chem Soc*, **99**, 5946 (1977)
- (+)-BPPM stands for (2*R*,4*R*)-N-(t-butoxycarbonyl)-4-diphenylphosphino-2-diphenylphosphino-methylpyrrolidine G L Baker, S J Fritschel, J R Stille, and J K Stille, *J Org Chem*, **46**, 2954 (1981) See also ref 1(b)
- (-)-BPPM stands for (2*S*,4*S*)-N-(t-butoxycarbonyl)-4-diphenylphosphino-2-diphenylphosphino-methylpyrrolidine K Achiwa, *J Am Chem Soc*, **98**, 8265 (1976)
- DIOP stands for 2,3-O-isopropylidene-2,3-dihydroxy-1,4-bis(diphenylphosphino)butane H B Kagan and T -P Dang, *J Am Chem Soc*, **94**, 6429 (1972)
- Chiral catalysts were prepared in situ by reacting chiral ligands with  $[\text{Rh}(\text{NBD})_2]\text{ClO}_4$  (NBD = norbornadiene) in degassed ethanol

(Received in Japan 24 April 1982)